Incidence of anesthetics drug induced malignant hyperthermia in Lady Reading Hospital (LRH), Peshawar, Pakistan
Paper Details
Incidence of anesthetics drug induced malignant hyperthermia in Lady Reading Hospital (LRH), Peshawar, Pakistan
Abstract
Malignant hyperthermia (MH) is a pharmacogenetic disorder and life-threatening syndrome of skeletal muscle with exposure to potent inhalational anesthetics (Halothane, desflurane) and depolarizing muscle relaxant (succinylcholine). To determine the incidence of anesthetic drug induced malignant hyperthermia in patients in lady reading hospital Peshawar. This cross-sectional study was carried out in duration of six months (February to August 2019) in lady reading hospital (LRH) Peshawar. The intension of this study was to determine the incidence of drug induced (MH) in patients who are going for surgical procedure under general anaesthesia especially exposure to inhalational agents and Suxamethonium. Ethical approval was taken from ethical committee of Khyber Medical University (KMU) and Leady Reading Hospital (LRH) Peshawar. Informed consent was taken from Participants. Demographics details and patient’s data were recorded and analysed through SPSS. Data of 424 patients were obtained in which males were 268 (63.2%) and female were 156 (36.8%). The mean age of the patients was 31.2±19.4. There was no case of malignant hyperthermia among these patients. The pinpoint incidence of malignant hyperthermia is unknown. In our study we are not find any case of malignant hyperthermia.
Bachand M. 1997 ‘Clinical reassessment of malignant hyperthermia in Abitibi-Temiscamingue’, Canadian Journal of Anaesthesia. Springer 44(7), pp. 696-701. DOI: 10.1007/bf03013380.
Brady JE. 2009 ‘Prevalence of Malignant Hyperthermia Due to Anesthesia in New York State, 2001–2005’, Anesthesia & Analgesia. Lippincott Williams and Wilkins 109(4), pp. 1162-1166. DOI: 10.1213/ane.0b013e3181ac1548.
David S. 2020. Beebe (no date) Malignant Hyperthermia in the Operating Room: Practice Essentials, Problem, Management. Available at: https://emedicine.medscape.com/article/2500077-overview (Accessed: 20 April 2020).
Gonsalves SG. 2013. ‘Using exome data to identify malignant hyperthermia susceptibility mutations’, Anesthesiology. The American Society of Anesthesiologists 119(5), pp. 1043-1053. DOI: 10.1097/ALN.0b013e3182a8a8e7.
Michael S, Phillips VKKSDLWFBABDHM. 1994. Substitution of Arg for Gly2433 in the human skeletal muscle ryanodine receptor is associated with malignant hyperthermia. Human Molecular Genetics. Oxford Academic.
Ording H. 1996. ‘Investigation of Malignant Hyperthermia Susceptibility in Denmark – PubMed’. Available at: https://pubmed.ncbi.nlm.nih.gov /8741205/ (Accessed: 20 April 2020).
Peng Philip W. 1995. ‘A clinical grading scale of predict malignant hyperthermia susceptibility’, Anesthesiology 31(4), pp. 305-309.
Bannister RA. 2012. ‘Dantrolene-Induced Inhibition of Skeletal L-Type Ca2+ Current Requires RyR1 Expression’, biomed research international p. 10. Available at: https://www.hindawi.com /journals /bmri/2013/390493/ (Accessed: 20 April 2020).
Riazi S, Kraeva N. 2014. ‘Malignant hyperthermia and the clinical significance of type-1 ryanodine receptor gene (RYR1) variants: proceedings of the 2013 MHAUS Scientific Conference’, Canadian Journal of Anesthesia. DOI: 10.1007/s12630-014-0227-5.
Riazi S, Larach MG. 2014. ‘Malignant hyperthermia in Canada: Characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands’, Anesthesia and Analgesia. Anesth Analg 118(2), pp. 381–387. DOI: 10.1213/ANE.0b013e3182937d8b.
Riazi S, Kraeva N, Hopkins PM. 2018. ‘Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept’, Anesthesiology. Lippincott Williams and Wilkins 128(1), pp. 168-180. DOI: 10.1097/ALN.0000000000001878.
Robinson R. 2006. ‘Mutations in RYR1 in malignant hyperthermia and central core disease’, Human Mutation. John Wiley & Sons, Ltd 27(10), pp. 977-989. DOI: 10.1002/humu. 20356.
Rosenberg H. 1994. ‘Malignant hyperthermia susceptibility’, Anesthesiology Clinics of North America. University of Washington, Seattle 12(3), pp. 513-535. DOI: 10.1111/j.1365-2044.1979.tb04865.x.
Rosenberg H. 2015. ‘Malignant hyperthermia: a review’, Orphanet Journal of Rare Diseases. BioMed Central Ltd 10(1), pp. 1-19. DOI: 10.1186/s13023-015-0310-1.
Rosero EB. 2009. ‘Trends and outcomes of malignant hyperthermia in the united states, 2000 to 2005’, Anesthesiology. Lippincott Williams and Wilkins 110(1), pp. 89-94. DOI: 10.1097/ALN. 0b013e318190bb08.
Schneiderbanger D. 2014. ‘Management of malignant hyperthermia: Diagnosis and treatment’, Therapeutics and Clinical Risk Management. Dove Medical Press Ltd pp. 355-362. DOI: 10.2147/ tcrm.s47632.
Strazis KP, Fox AW. 1993. ‘Malignant hyperthermia: A review of published cases’, Anesthesia and Analgesia. Anesth Analg pp. 297-304. DOI: 10.1213/00000539-199308000-00014.
Strazis, Kimberly Prather and Fox AW. 1993. ‘Malignant Hyperthermia’, Anesthesia & Analgesia 77(2), pp. 297-304. DOI: 10.1213/00000539-199308000-00014.
Wappler F. 2001. Malignant hyperthermia : European Journal of Anaesthesiology (EJA). Available at: https://journals.lww.com/ ejanaesthesiology /fulltext /2001/10000/malignant_hyperthermia.2.aspx (Accessed: 20 April 2020).
Zhu X. 2004. ‘The calmodulin binding region of the skeletal ryanodine receptor acts as a self-modulatory domain’, Cell Calcium. Elsevier Ltd 35(2), pp. 165-177. DOI: 10.1016/j.ceca.2003.09.002.
Muhammad Tayyeb, Muhammad Ali, Sher Muhammad, Bashir Ul Haq, Arsalan Khan, Muhammad Qasim Jan, Muhammad Abbas, 2020. Incidence of anesthetics drug induced malignant hyperthermia in Lady Reading Hospital (LRH), Peshawar, Pakistan. Int. J. Biosci., 17(1), 232-237.
Copyright © 2020 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.